Quantitative proteomic determination of diethylstilbestrol action on prostate cancer.

[1]  M. Rouprêt,et al.  Current role of diethylstilbestrol in the management of advanced prostate cancer , 2012, BJU international.

[2]  R. Vessella,et al.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression , 2011, Oncogene.

[3]  D. Gillatt,et al.  Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel , 2011, British Journal of Cancer.

[4]  G. Rashid,et al.  The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells , 2010, The Prostate.

[5]  S. Koochekpour,et al.  Androgen receptor signaling and mutations in prostate cancer. , 2010, Asian journal of andrology.

[6]  H. Miyake,et al.  Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. , 2010, Urologic oncology.

[7]  J. Cuzick,et al.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement , 2009, British Journal of Cancer.

[8]  Jo Vandesompele,et al.  RTPrimerDB: the portal for real-time PCR primers and probes , 2008, Nucleic Acids Res..

[9]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[10]  P. Ekman,et al.  Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  P. Singh,et al.  A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. , 2008, European journal of cancer.

[12]  W. Grody,et al.  Expression of arginase II in prostate cancer. , 2008, International journal of oncology.

[13]  L. Rejtõ,et al.  Hormonal regulation of IGFBP‐2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model , 2007, Journal of cellular physiology.

[14]  C. Ryan,et al.  Diethylstilbestrol and docetaxel , 2007, Cancer.

[15]  M. Sadar,et al.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. , 2006, Cellscience.

[16]  Guanghui Wang,et al.  Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. , 2006, Journal of proteome research.

[17]  T. Oyama,et al.  Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer , 2005, British Journal of Cancer.

[18]  S. Bustin,et al.  Evidence for a link between IGF-I and cancer. , 2004, European journal of endocrinology.

[19]  W. Pitts,et al.  The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. , 2003, The Journal of urology.

[20]  David C. Smith,et al.  Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma , 2003, Cancer.

[21]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[22]  W. Oh.  The evolving role of estrogen therapy in prostate cancer. , 2002, Clinical prostate cancer.

[23]  S. Malkowicz.  The role of diethylstilbestrol in the treatment of prostate cancer. , 2001, Urology.

[24]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[25]  Guido Kroemer,et al.  Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.

[26]  J. Liehr,et al.  Estrogens as endogenous genotoxic agents--DNA adducts and mutations. , 2000, Journal of the National Cancer Institute. Monographs.

[27]  F. Chinegwundoh,et al.  Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone‐releasing hormone analogues and orchidectomy , 2000, BJU international.

[28]  E. Solary,et al.  HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[30]  K. Pienta,et al.  A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. , 1998, Urology.

[31]  H. Matsuzaki,et al.  Activation of protein kinase B (Akt/RAC‐protein kinase) by cellular stress and its association with heat shock protein Hsp27 , 1997, FEBS letters.

[32]  F. Guillé,et al.  Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma , 1996, Cancer.

[33]  R. Fine,et al.  Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. , 1996, Journal of the National Cancer Institute.

[34]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[35]  J. Boyle,et al.  Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. , 1993, Genomics.

[36]  H. Pitot,et al.  Transcriptional control of ornithine aminotransferase synthesis in rat kidney by estrogen and thyroid hormone. , 1984, The Journal of biological chemistry.

[37]  P. McCann,et al.  Polyamine metabolism and function. , 1982, The American journal of physiology.

[38]  D. Byar.  The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.

[39]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[40]  I. Leav,et al.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. , 2001, The American journal of pathology.

[41]  Gary R. Grotendorst,et al.  CCN proteins are distinct from and should not be considered members of the insulin-like growth factor-binding protein superfamily. , 2000, Endocrinology.

[42]  D. Edwards,et al.  Estrogen regulation of specific proteins as a mode of hormone action in human breast cancer. , 1983, Biomembranes.